ILA — Island Pharmaceuticals Share Price
Last trade - 00:00- AU$26.33m
- AU$22.34m
- AU$0.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.77 | ||
| Price to Tang. Book | 6.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 20,733.49 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.19% | ||
| Return on Equity | -143.22% | ||
| Operating Margin | -251742.52% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | n/a | 0.01 | 0 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Island Pharmaceuticals Ltd is an Australia-based drug repurposing company. The Company is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
Directors
- Paul MacLeman CHM
- David Foster CEO
- Peter Webse SEC
- Albert Hansen NED (57)
- David Brookes NID
- Anna Lavelle NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 25th, 2020
- Public Since
- April 13th, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 181,596,795
- Address
- Suite 201, 697 Burke Road, MELBOURNE, 3124
- Web
- https://www.islandpharmaceuticals.com/
- Phone
- +61 390920475
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for ILA
Similar to ILA
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 21:22 UTC, shares in Island Pharmaceuticals are trading at AU$0.15. This share price information is delayed by 15 minutes.
Shares in Island Pharmaceuticals last closed at AU$0.15 and the price had moved by +173.58% over the past 365 days. In terms of relative price strength the Island Pharmaceuticals share price has outperformed the ASX All Ordinaries Index by +163.67% over the past year.
There is no consensus recommendation for this security.
Find out moreIsland Pharmaceuticals does not currently pay a dividend.
Island Pharmaceuticals does not currently pay a dividend.
Island Pharmaceuticals does not currently pay a dividend.
To buy shares in Island Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.15, shares in Island Pharmaceuticals had a market capitalisation of AU$26.33m.
Here are the trading details for Island Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ILA
Based on an overall assessment of its quality, value and momentum Island Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Island Pharmaceuticals. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +19.33%.
As of the last closing price of AU$0.15, shares in Island Pharmaceuticals were trading +10.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Island Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Island Pharmaceuticals' management team is headed by:
- Paul MacLeman - CHM
- David Foster - CEO
- Peter Webse - SEC
- Albert Hansen - NED
- David Brookes - NID
- Anna Lavelle - NID